Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Clearmind aims to use a psychedelic to treat alcoholism

By Brian Buntz | March 10, 2022

ClearmindThe psychoactive compound 5-methoxy-2-aminoindane (MEAI) is unique among psychedelics with therapeutic potential. 

First, the drug could be self-administered. Second, it is patented, unlike psychedelics such as LSD, psilocybin, MDMA and ketamine. And while psychedelic drug developers tend to focus on indications such as depression, anxiety and post-traumatic stress disorder, MEAI could potentially treat alcoholism. 

MEAI was first described in 1980 as a non-hallucinogenic recreational drug. Early users of it claimed it reduced their desire to drink. 

“It is an unusual situation where you have human testimonies, and now we’re going back to animals,” said Adi Zuloff-Shani, CEO of Clearmind Medicine (CSE:CMNDF), the developer of the drug. 

MEAI has “great potential to help with one of the most devastating addictions society knows today, which is alcoholism,” Zuloff-Shani said. 

Like a number of other psychedelics companies, Clearmind Medicine is headquartered in Vancouver, Canada. It conducts R&D in Israel. 

According to Mayo Clinic Proceedings, some 2 billion people overuse alcohol, contributing to approximately 6% of all deaths worldwide.

Adi Zuloff-Shani

Adi-Zuloff-Shani, Ph.D.

MEAI could limit cravings for alcohol while also inducing an alcohol-like feeling of euphoria on its own. Describing it as a “very light psychedelic,” Zuloff-Shani said MEAI produces an experience similar to a glass of wine or beer. “It’s a very euphoric, tipsy but controlled feeling,” said Zuloff-Shani. 

Testimonials from users who took MEAI in informal settings report that it reduced their alcohol consumption.

There are plans for a Phase 1 study of the drug. 

At present, the treatment landscape for alcoholism is sparse. FDA has approved three medications: acamprosate, disulfiram and naltrexone. 

Preclinical data suggest MEAI is safe. A study published in Toxicology and Applied Pharmacology found MEAI had a short plasma and brain half-life, while a paper published in Psychopharmacology concluded that ring-substituted derivatives such as MEAI “may produce 3,4-methylenedioxymethamphetamine (MDMA)-like effects but with less abuse liability.” 

“We want to ensure that it is safe and efficacious,” Zuloff-Shani said. “We don’t want to switch one addiction with another.”

Humans who have tried MEAI report it was not habit-forming. “None of the people who tried it said that they wanted to continue consuming it,” Zuloff-Shani said. 

“That was very encouraging because when you try to treat addiction, you don’t want people to feel the need to control their behavior,” Zuloff-Shani said. 

“You want to give them a good tool that will give them to switch off their willingness to go to drink something — to have them think, ‘I had enough I don’t want to anymore.'”


Filed Under: Psychiatric/psychotropic drugs, Women in Pharma and Biotech
Tagged With: alcoholism, Clearmind Medicine, FDA, MEAI, psychedelics
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE